GlassScriptPhysician profile
Janet L Wang
NPI 1760629158
$491.58
in general payments reported to CMS, 2019-2025
12 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.75 · 2021: $23.94 · 2022: $25.90 · 2023: $26.34 · 2024: $287 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.93 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $80.01 | 2024-2025 | Reblozyl |
| Janssen Biotech, INC. | $62.02 | 2023-2025 | Akeega, Balversa, Erleada |
| E.R. Squibb & Sons, L.L.C. | $61.90 | 2024-2025 | Opdivo |
| Glaxosmithkline, LLC. | $54.83 | 2024 | Jemperli, Zejula, Ojjaara |
| Acrotech Biopharma INC. | $49.84 | 2021-2022 | |
| Array Biopharma INC | $42.10 | 2024 | Mektovi, Braftovi, Tukysa |
| Amgen INC. | $39.61 | 2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Sumitomo Pharma America, INC. | $25.45 | 2024 | Orgovyx |
| Takeda Pharmaceuticals U.S.A., INC. | $24.01 | 2024 | Alunbrig |
| Stemline Therapeutics INC. | $16.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.